Wells Trecaso Financial Group LLC Has $4.55 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Wells Trecaso Financial Group LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 11,228 shares of the medical research company’s stock after purchasing an additional 290 shares during the quarter. Thermo Fisher Scientific accounts for 1.4% of Wells Trecaso Financial Group LLC’s portfolio, making the stock its 24th biggest holding. Wells Trecaso Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $4,553,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC grew its stake in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 3.6%

NYSE:TMO opened at $543.88 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $205.37 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The firm’s 50 day moving average is $482.58 and its 200 day moving average is $447.76. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on TMO shares. Raymond James Financial reiterated an “outperform” rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Finally, HSBC restated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.